Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a Large Randomized, Prospective, Single-Center Study.


Journal

Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373

Informations de publication

Date de publication:
2020
Historique:
received: 03 08 2019
accepted: 16 10 2019
pubmed: 5 12 2019
medline: 12 2 2021
entrez: 5 12 2019
Statut: ppublish

Résumé

Enhanced recovery after surgery (ERAS) concepts are implemented in various surgical disciplines. For patients undergoing radical cystectomy, prospective data are still rare. In the year 2014, our group could prove significant benefits of ERAS for these patients in a prospective randomized study compared to a conservative regimen. To evaluate long-term follow-up results of ERAS concepts in patients undergoing radical cystectomy for bladder cancer. Of the 101 patients who had initially prospectively been randomized to ERAS or a conservative regimen, 35 patients could be included in the study. Median follow-up time was 83 months. Primary end point assessed quality of life. Secondary end points were cancer-specific survival and overall survival. Five to seven years after the initial inclusion to the study, no significant difference regarding quality of life parameters was detected (p values range between 0.112 and 0.970). Continence status in patients with neobladder showed no significant differences between ERAS and conservative regimens (p = 0.785). Cancer-specific survival in the ERAS group did not differ significantly from that in the conservative group (49 vs. 58%, p = 0.725). While ERAS represents an excellent way to improve postoperative reconvalescence and quality of life in the short-term follow-up, our data do not support the idea that there is also a long-term effect in terms of quality of life issues.

Identifiants

pubmed: 31801154
pii: 000504236
doi: 10.1159/000504236
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-61

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Brigitte Katharina Ziegelmueller (BK)

Department of Urology, Ludwig-Maximilians-University, Munich, Germany, Brigitte.Ziegelmueller@med.uni-muenchen.de.

Jan-Friedrich Jokisch (JF)

Department of Urology, Ludwig-Maximilians-University, Munich, Germany.

Alexander Buchner (A)

Department of Urology, Ludwig-Maximilians-University, Munich, Germany.

Tobias Grimm (T)

Department of Urology, Ludwig-Maximilians-University, Munich, Germany.

Alexander Kretschmer (A)

Department of Urology, Ludwig-Maximilians-University, Munich, Germany.

Gerald Bastian Schulz (GB)

Department of Urology, Ludwig-Maximilians-University, Munich, Germany.

Christian Stief (C)

Department of Urology, Ludwig-Maximilians-University, Munich, Germany.

Alexander Karl (A)

Department of Urology, Barmherzige Brüder Hospital, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH